

OLSON & HIERL, LTD.

20 NORTH WACKER DRIVE

36TH FLOOR

CHICAGO, ILLINOIS 60606

(312) 580-1180

FAX TRANSMITTAL SHEET

FAX NO. (312) 580-1189

Date: November 5, 1999Send to No.: 703-308-7922To: **Examiner E. Huang
Art Unit 1612**From: **Talivaldis Cepuritis (Reg. No. 20,818)**Re: **Serial No. 09/171,697; Tabakoff et al.**Number of Pages: 4 (Does Not Include This Transmittal Sheet)**SPECIAL INSTRUCTIONS FOR THE RECEIVING PARTY ONLY:****A copy of the Preliminary Amendment filed with the PTO on 17 June 1999 will be hand delivered to you on Monday or Tuesday of next week.**

THE MESSAGE TRANSMITTED UNDER THIS COVER IS INTENDED FOR THE NAMED RECIPIENT ONLY, AND MAY CONTAIN BUSINESS CONFIDENTIAL INFORMATION, OR INFORMATION SUBJECT TO ATTORNEY-CLIENT PRIVILEGE OR ATTORNEY WORK PRODUCT IMMUNITY. IN THE EVENT THIS MESSAGE IS RECEIVED AT A LOCATION WHERE IT CANNOT BE CONVEYED TO THE NAMED RECIPIENT, KINDLY NOTIFY THE SENDER IMMEDIATELY BY TELEPHONE/FACSIMILE (IF LONG DISTANCE, PLEASE CALL COLLECT), AND RETURN THE RECEIVED MESSAGE TO US BY MAIL.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Boris Tabakoff et al.)
)
Serial No. 09/171,697)
)
Filed: October 23, 1998)
) Group Art Unit 1612
For: COMPOUNDS, COMPOSITIONS AND)
)
METHOD SUITABLE FOR AMELIORA-)
)
TION OF WITHDRAWAL SYNDROMES)
)
AND WITHDRAWAL-INDUCED BRAIN)
)
DAMAGE)
)
Examiner: Evelyn Mei Huang)

RESPONSE AND AMENDMENT UNDER RULE 111

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

In response to the Office Action dated 27 August 1999, please amend this application as follows:

In the Claims:

Cancel claims 1-10, inclusive.

Rewrite claim 11 to read:

11(Amended). The compound [composition] of claim 12 [10] wherein the compound is selected from the group consisting of (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline, (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline methyl ester, and N-phenyl, N-[2-methoxy]phenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline.

Rewrite claim 12 to read:

12(Twice Amended). A compound [suitable] for treating withdrawal syndromes manifested in a patient suffering withdrawal symptoms and/or withdrawal-induced brain damage [which comprises administering an effective ameliorating amount of a compound] and having the [general] formula (I):

official
208 11/5/99